AFRICA UNIVERSITY
(A United Methodist-Related Institution)

ASSESSMENT OF THE INDIRECT IMMUNOFLUORESCENCE ANTIGEN TEST AND FORMOL-ETHER CONCENTRATION TECHNIQUE IN THE DIAGNOSIS OF *SCHISTOSOMA MANSONI* AT LANCET CLINICAL LABORATORIES, ZIMBABWE

BY

RYAN TANAKA MANYAU

2024

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF BACHELOR OF MEDICAL LABORATORY SCIENCES HONOURS IN THE COLLEGE OF HEALTH, AGRICULTURE AND NATURAL SCIENCES

Abstract

Schistosomiasis, caused by the Schistosoma mansoni parasite, is a neglected tropical disease with a significant burden in Zimbabwe. Accurate diagnosis is crucial for effective treatment and control strategies. This study aimed to compare the diagnostic performance and cost-effectiveness of the Indirect Immunofluorescent Antibody Test (IFAT) and the Formol-Ether Concentration (FEC) technique for detecting Schistosoma mansoni infections at Lancet Clinical Laboratories in Zimbabwe. A retrospective cross-sectional study was conducted using laboratory records from Lancet Clinical Laboratories in Harare, Zimbabwe from October 2022 to March 2023. Data on IFAT and FEC test results, along with demographic and clinical information, were collected for individuals suspected of Schistosoma mansoni infection. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated for both techniques.McNemar's test was used to assess the discordance between IFAT and FEC results. Cost-effectiveness was evaluated by calculating the incremental cost-effectiveness ratio (ICER). Turnaround time (TAT) was evaluated by by calculating the average TAT and determining the laboratory workload and workflow of FEC and IFAT. The study had total of 105 samples that were tested with IFAT and FEC method. FEC, the sensitivity was 39.5%, specificity was 100%, PPV was 100%, NPV was 70.4%, and diagnostic accuracy was 75.2% accordingly. While with IFAT, the sensitivity was 100%, specificity was 96.8%, PPV was 95.6%, NPV was 100%, and diagnostic accuracy was 98.1% accordingly. McNemar's test showed there is a significant discordance between the two techniques($\mathbf{p_a + p_b \neq p_a + p_c}$ and p-value < 0.05 significance level). This means there is a substantial difference in the performance of the two diagnostic methods FEC and IFAT. However, the significant discordance between the two techniques highlighted the need for accurate and sensitive diagnostic methods, like IFAT. Next was the cost-effectiveness analysis that showed the IFAT method had an incremental cost-effectiveness ratio (ICER) of 0.38 US dollars per additional case detected compared to FEC, suggesting that IFAT, though its more expensive, is a cost-effective option for Schistosoma mansoni diagnosis. Lastly the turnaround time analysis showed that the average TAT 1hour 38minutes for FEC and 36 hours 30minutes along with the workload and workflow of both methods were acceptable. Overall, IFAT demonstrated a superior diagnostic performance compared to FEC, with higher sensitivity and diagnostic accuracy in detecting Schistosoma mansoni infections though being expensive and having a longer TAT. FEC was seen to be more cost-effective than IFAT and time effective. The findings of this study provide valuable insights into the performance, cost-effectiveness, and operational considerations of IFAT and FEC techniques for Schistosoma mansoni diagnosis in Zimbabwe, informing decision-making and quality improvement initiatives in healthcare.

Key Words: *Schistosoma mansoni*, diagnostic methods

Declaration

I declare that this dissertation is my original work except where sources have been cited and acknowledged. The work has never been submitted, nor will it be submitted to another university for the award of any degree.

RYAN MANYAU		24/02/24
Student's Full Name	**Student's Signature**	**Date**
GARIKAI MALUNGA		24/02/24
Supervisor's Full name	**Supervisors' Signature**	**Date**

Acknowledgements

Firstly, I thank God for the guidance and favour shown to me through the wisdom they imparted on me. I would like to thank my mother, Dr Salome Manyau for advising me on how to get through the process and praying for me. To my father, Mr Fungai Manyau, thank you for being an example and motivation to move forward, push through and do what needs to be done without complaint. I would like to thank my colleagues at Africa University and Lancet Clinical Laboratories who helped me in the research process. To my grandparents, thank you for accommodating me during the period of the study. Last but not least I would like to thank my supervisor for going above and beyond in helping me complete this dissertation.

List of acronyms and Abbreviations

CCA	**-**	Circulating Cathodic Antigen
CEA	**-**	Cost Effectiveness Analysis
DALYs	-	Disability-Adjusted Life Years
FEC	-	Formol-Ether Concentration
FITC	-	Fluorescein isothiocyanate
ICER	**-**	Incremental Cost-Effectiveness Ratio
IFAT	-	Indirect Immunofluorescent Antibody Test
MDA	-	Mass Drug Administration
NTDs	-	Neglected Tropical Diseases
POC-CCA	**-**	Point-of-care Circulating Cathodic Antigen
WASH	-	Water, Sanitation and Hygiene

Table of Contents

List of Tables

List of Figures

List of Appendices

CHAPTER 1 INTRODUCTION

1.1 Introduction

This chapter introduces the research process. Starting with an overview of schistosomiasis distribution as a neglected tropical disease, its pathophysiology and the diagnostic techniques employed internationally and in Zimbabwe. The problem statement given, elaborating how the problem at hand prompted the researcher to undertake this study. The study objectives are enlisted as well as the related research questions. The delimitations and limitations of the study are stated. Lastly, the chapter will end with the justification of why the researcher thinks the study is of public health importance.

1.2 Background of the Study

1.2.1 Burden of Schistosomiasis

Schistosomiasis, also known as bilharzia, is a neglected tropical disease caused by parasitic worms of the genus Schistosoma. It affects over 200 million people worldwide (WHO, 2023) and causes significant morbidity and mortality in sub-Saharan Africa (Gryseels et al., 2006). A review estimated that more than 200,000 deaths occur each year due to schistosomiasis in this region alone. The disease can present with acute symptoms or be chronic and asymptomatic but still result in a loss of over 1.53 million disability-adjusted life years globally (Gryseels et al., 2006). Untreated it leads to recurring anaemias and failure to thrive in children and when it develops into a more chronic disease can lead to portal-hypertension, kidney disease, bladder cancers, and female genital schistosomiasis in adults (WHO, 2022) Preventive chemotherapy, or mass drug administration (MDA), using praziquantel is the mainstay of control((Nausch et al., 2014).



[Source:https://www.thelancet.com/cms/attachment/2119347870/2092561921/gr1.jpg]

Figure 1: Worldwide distribution of schistosomiasis

Based on the map presented above, Schistosoma is a disease of poverty with developed non-tropical regions like Northern America and western Europe having a lower risk of schistosomiasis and are not endemic. However, in developing tropical or temperate regions - particularly sub-Saharan Africa, the Middle East, Asia and Latin America - over 1 to 10 million people are at risk of contracting this disease(Mutapi et al., 2017). These figures represent the burden of disease post MDA showing there is a long way till its elimination as a public health problem (EPHP) in 100% of affected countries by 2031 (Control of Neglected Tropical Diseases (NTD), 2021)(Mutapi et al., 2017). It is endemic to these regions because there are low-income rural communities without access to potable water, proper sanitation, and adequate healthcare facilities (Aula et al., 2021). Sub-Saharan Africa(SSA) constitutes about 13% of the world's population but accounts for up to 90% of cases (van der Werf et al., 2003) mainly attributed to two species of Schistosoma : *S.Mansoni and S.Haematobium* (Aula et al., 2021).

Zimbabwe, by 2023, noted that bilharzia is among the most common Neglected Tropical Diseases (NTDs), along with intestinal worms, elephantiasis and blinding trachoma(WHO.,

2023). A Geospatial survey conducted in Zimbabwe revealed Mashonaland Central and Mashonaland East provinces had the highest prevalence rates for schistosomiasis in 2021; Mashonaland Central recorded a prevalence rate of 19%, followed by Mashonaland East at 13.6%, Manicaland at11.8 %, Masvingo at 10.8% while the rest of the provinces record around 5% (Rebollo et al., 2021). The distribution of bilharzia prevalence in Zimbabwe indicates a close relationship with variability of surface water, especially in northern regions of Zimbabwe, which have the highest temperature and rainfall, and, where most streams have some water all year round, the prevalence of *Schistosoma mansoni* and *Schistosoma haematobium* is at its highest (Woolhouse & Chandiwana, 1990).

1.2.2 Pathophysiology of Schistosomiasis

Schistosomiasis is a parasitic disease caused by infection with the Schistosoma parasite. The pathophysiology of schistosomiasis involves a complex interplay between the parasite and the human immune system.

Schistosome ova hatch into miracidia penetrate snail tissue and develop into sporocysts. The sporocyst is releases free-swimming cercariae into freshwater, which then penetrates the skin of an individual who comes into contact with the contaminated water(CDC,2019). The cercariae then migrate through the bloodstream to the liver, where they mature into adult worms. The adult worms eventually migrate to their final destination, which is typically the blood vessels of the urinary(*S.haematobium*) or intestinal systems(*S.mansoni*)(Clerinx & Van Gompel, 2011). During their migration and habitation in the blood vessels, the adult worms release eggs that become trapped in the surrounding tissues. The presence of these eggs triggers an immune response in the host, which plays a major role in the pathophysiology of schistosomiasis.

The immune response to schistosomiasis has both innate and adaptive immune components. The initial response involves the activation of various immune cells, such as macrophages, eosinophils, and neutrophils, which recognize the parasite and release inflammatory mediators. This leads to local tissue damage and contributes to the clinical manifestations of the disease.

Additionally, the parasite has developed mechanisms to evade the host immune system. The Schistosoma parasite releases a variety of immunomodulatory molecules that interfere with the host immune response. These molecules can suppress the function of immune cells and help the parasite establish a chronic infection.

The adaptive immune response to schistosomiasis is primarily mediated by T cells. CD4+ T helper cells play a crucial role in orchestrating the immune response by differentiating into different subsets, such as Th1, Th2, or Th17 cells (Zhu & Zhu, 2020). Th1 cells primarily produce pro-inflammatory cytokines, such as interferon-gamma (IFN-γ), which help in the elimination of the parasite. Th2 cells, on the other hand, produce anti-inflammatory cytokines, such as interleukin-4 (IL-4) and interleukin-13 (IL-13), which promote tissue repair and are associated with the pathology of chronic schistosomiasis.Chronic schistosomiasis is characterized by fibrosis and granuloma formation around the eggs trapped in the tissues. Fibrosis occurs due to the excessive deposition of collagen by activated fibroblasts, leading to tissue scarring and dysfunction (Masamba & Kappo, 2021). Granuloma formation involves the recruitment and activation of immune cells, such as macrophages, lymphocytes, and eosinophils, around the eggs(Schwartz & Fallon, 2018). Granuloma formation is part of the bodies protective mechanism to contain the parasite, it can also cause tissue damage and disease.

1.3 Laboratory diagnosis of schistosomiasis

Early and accurate diagnosis of *Schistosoma mansoni* infection is very crucial for effective management and control of disease (Sassa et al., 2020). In the history of Schistosome diagnostics, the prevalence of infection in a specific region was determined by employing the Kato-Katz faecal smear technique for *S. mansoni* infections, while *S. haematobium* infections were assessed via urine filtration and/or questionnaires identifying visible haematuria.(Aula et al., 2021). Since then along with the old techniques there are numerous new diagnostics using the principles of microscopy, serology, DNA amplification and imaging.

The gold-standard test for diagnosis of schistosomiasis is the detection of parasite eggs in stool and urine samples under the microscope as seen in Figure 2 and Figure 3 below. Intestinal schistosomiasis is diagnosed by faecal sedimentation techniques: the Kato-Katz smear technique, the Formol-Ether Concentration technique, and the wet-mount technique. Urogential schistosomiasis is diagnosed by urine sedimentation techniques: filtration and wet-mount technique (Chala, B., 2023). These techniques rely on light microscopy to visualize parasite ova in the faecal or urine sediment or sample. Sedimentation involves the use of solutions of lower specific gravity than the parasitic organisms ova, thus concentrating the latter in the sediment during centrifugation and subsequent microscopic examination of the sediment unstained.

The formal-ether technique involves the concentration and visualization of parasite eggs in a stool sample for S.*mansoni* diagnosis. The sample is mixed with a formalin-ether solution, which causes the eggs to float to the top. The liquid is then poured off, and a thin sediment is left, which is examined under a microscope for the presence of Schistosoma eggs. This method is relatively sensitive and allows for the detection of low levels of infection.(WHO.,2023). This method is relatively sensitive and allows for the detection of low levels of infection.The Kato-

Katz technique is a widely used method for detecting and quantifying helminth eggs in faecal samples. It involves preparing a smear of stool on a microscope slide using a template that ensures a specific volume of faecal material is collected (Rabello et al., 1992). A cellophane strip is placed on top of the smear, and a fixative solution is added to dissolve the smear and preserve parasite eggs. After a few minutes, the strip is removed, and the slide is examined under a microscope to identify and count the eggs (Garcia & Reddy, 2010). The wet-mount technique, on the other hand, is a simpler and quicker method for detecting *Schistosoma mansoni* eggs in faecal and urine samples. It involves mixing a small amount of faeces or urine sediment with a drop of saline or water on a microscope slide and placing a cover-slip on top (Cheesbrough, 2006). The sample is then examined under a microscope, allowing for the direct observation of live parasite eggs and other organisms present in the sample. Lastly is the urine filtration technique where a urine sample concentrated by sedimentation, centrifugation, or filtration and forced over a paper or nitrocellulose filter. The filtrate is then observed for Schistosoma ova viewed under a microscope. The Kato-Katz technique is regarded as a more reliable method for quantifying helminth eggs due to its ability to process larger volumes of faecal samples and provide more accurate egg counts (Garcia, 2010; Katz et al., 1972).Whilst the urine filtration technique is the gold standard for identification urogential schistosomiasis(Gryseels.,2006). While these techniques have been widely used for many years, they have several limitations, including their low sensitivity in detecting early or light infections,the need for multiple samples, and the requirement for skilled microscopist.



[Source:https://www.cdc.gov/dpdx/schistosomiasis/images/2/S_haematobium_egg_2]

Figure 2. Schistosoma haematobium ova in a wet mount of urine concentrates



[Source:https://www.cdc.gov/dpdx/schistosomiasis/images/1/S_mansoni_egg_WI1.jpg]

Figure 3. *Schistosoma mansoni* ova as seen in faecal sediment

In recent years, serological methods such as indirect immunofluorescent antibody test (IFAT), enzyme-linked immunosorbent assay (ELISA), and immunochromatographic tests have shown promising results in detecting *Schistosoma mansoni* infection (Fukushige et al., 2019).IFATs involve fixing specific schistosome cercariae onto a solid surface and applying patient sera in serial dilutions. The antibodies in the patient's serum bind to the cercariae surface antigens,

which are then tagged by a secondary antibody with a visible fluorescent marker. Analysis under a fluorescent microscope allows for the detection of visible complexes on the cercariae surface (Fukushige et al., 2019).ELISA tests, on the other hand, detect antigens released by the schistosome parasite or antibodies produced by the immune system in response to the infection. In this assay, a solid surface, such as a microplate, is coated with the target antigen or antibody. If the target molecule is present in the patient's sample, it will bind to the coated molecules. The presence of the target molecule is detected by adding an enzyme-linked secondary antibody or antigen, followed by a substrate that produces a measurable signal, usually a color change. The intensity of the signal indicates the presence and concentration of the target molecule, allowing for the diagnosis of schistosomiasis (Fukushige et al., 2019).Immunochromatographic tests, including rapid diagnostic tests (RDTs) or lateral flow assays, are simple point-of-care tests. These tests utilize a test strip with a nitrocellulose membrane containing specific capture molecules for the Schistosome antigen or antibody. When the patient's sample, typically blood or urine, is added to the test strip, the target molecule, if present, will bind to the capture molecule and form a visible line as the sample travels along the strip. The appearance of the line indicates a positive result for schistosomiasis (Fukushige et al., 2019).These serological tests are highly sensitive and can detect early infections before the appearance of eggs in stool samples. Additionally, they have the advantage of being less labor-intensive and requiring less expertise compared to traditional parasitological techniques (Fukushige et al., 2019).

Next are DNA-based diagnostic techniques such as polymerase chain reaction (PCR) used to detect the schistosome DNA. Out of the numerous diagnostic techniques schistosome DNA using DNA amplification techniques including polymerase chain reaction (PCR) provides valuable options to the traditional microscopic and serological methods, due to accuracy, high

sensitivity, and the capacity to detect early pre-patent infections. Therefore, DNA-based methods represent important screening tools, particularly in endemic areas with ongoing control programs where infection prevalence and intensity have been or are being reduced to very low levels.(Weerakoon et al., 2018)

Lastly imaging techniques and biopsies are used to detect the damage done by the pathophysiological processes unique to schistosome worms. Imaging techniques such as ultrasonography, magnetic resonance imaging (MRI), and computed tomography (CT) scans are commonly used for the diagnosis of bilharzia (Sah et al., 2015). Ultrasonography utilizes sound waves to produce images of organs, allowing the detection of liver and spleen enlargement, as well as urinary or gastrointestinal abnormalities. On the other hand, MRI employs a magnetic field and radio waves to create highly detailed images, enabling the identification of complications like bladder wall thickening or renal abnormalities. CT scans, which combine X-rays and computer technology, are particularly helpful in detecting liver and spleen issues through the production of cross-sectional images (WHO, 2023). In addition to imaging, biopsies, specifically rectal and liver biopsies, are performed to confirm the presence of Schistosoma eggs and evaluate the extent of damage caused by the parasite.

1.4 Problem Statement

Schistosoma mansoni is the second most significant parasitic infection after malaria that affects millions of people in Zimbabwe (Chitsulo, L.,et.al. 2000). The disease burden persists in the Sub-Saharan region due to inadequate and inaccurate diagnostic methods used in primary healthcare facilities which are limited to the Formol-Ether Concentration technique. This method is inaccurate at detecting the parasite in faeces because it needs multiple samples over a long period and multiple examinations of the sample by a skilled microscopist and by then the

patients succumb to the disease receive a misdiagnosis such as celiac disease (Nunes, V.,2022) or decide to forgo treatment. Therefore under-diagnosis and misdiagnosis of gastrointestinal schistosomiasis occur. However, a few private laboratories across Zimbabwe, such as Lancet Clinical Laboratories, use more accurate methods such as serology and molecular diagnostics. During my internship at Lancet Clinical Laboratory, I used the indirect immunofluorescent antigen test (IFAT) alongside the formol-ether concentration (FEC) technique for *S. mansoni* diagnosis on samples from all over Zimbabwe. I noted that most of the patients who had their faeces screened for bilharzia using the FEC technique turned out negative whilst the IFAT on the patients serum turned out positive in numerous cases this suggests a discordance between the two methods. Therefore an assessment of the two methods was done.

1.5 Research Objectives

1.5.1 Broad Objective

The main objective of the study was to compare the indirect immunofluorescent antigen test (IFAT) and the formol-ether concentration technique (FEC) in the detection of *Schistosoma mansoni* infections in samples processed at Lancet Clinical Laboratory in Harare from October 2022 to March 2023.

1.5.2 Specific Objectives

1 Compare the diagnostic accuracy and sensitivity of the IFAT and FEC at Lancet Clinical Laboratory from October 2022 to March 2023

2 Evaluate the turnaround time for obtaining results using the IFAT and FEC at Lancet Clinical Laboratory from October 2022 to March 2023

3 Assess the cost-effectiveness of the IFAT and FEC at Lancet Clinical Laboratory from October 2022 to March 2023.

1.6 Research Questions

1 What are the diagnostic accuracy and sensitivity of the IFAT and FEC at Lancet Clinical Laboratory from October 2022 to March 2023?

2 What are the turnaround times for obtaining results using the IFAT and FEC at Lancet Clinical Laboratory from October 2022 to March 2023?

3 What is the cost-effectiveness of the IFAT and FEC at Lancet Clinical Laboratory from October 2022 to March 2023?

1.7 Study Justification

Schistosoma mansoni is a gastrointestinal parasite that is traditionally diagnosed by the detection of its ova under a microscope through Formol-Ether Concentration techniques in low-resource settings like in Zimbabwe however private laboratories such as Lancet Laboratories have ushered in the use of indirect immunofluorescent antibody tests(IFAT) for the detection of antibodies against the parasite. Preliminary results show there is discordance between IFAT and the formol-ether technique which could show that *Schistosoma mansoni* is being under-diagnosed in places where diagnosis is limited to using the Formol-Ether Concentration techniques alone and low endemicity. The severity of under-diagnosis can be ascertained by this study. Hence this study was seeking to provide scientific evidence on the accuracy of the diagnostic methods to show the

need for increased usage of IFAT in early schistosomiasis diagnostics and treatment policies across primary healthcare facilities.

1.8 Study Delimitations

This study utilized data from Lancet laboratory sites across Zimbabwe from October 2022 to March 2023. Medical records of patients (≥ 5 years) were examined for S. *mansoni* infections based on laboratory-confirmed diagnoses using the two standard diagnostic techniques Kato-Katz faecal sediment examination and the indirect immunofluorescent antigen test (IFAT). Data came from Lancet labs located in Bindura, Victoria Falls, Masvingo, Gweru, Harare, Mutare and Bulawayo.

1.9 Study Limitations

The study had a limited to a small sample size and sampling frame due to the test exclusive being provided at Lancet Laboratories for the entirety of Zimbabwe from a few locations. The study may have been affected by inter-observer variability because the FEC test was done by different scientists from different laboratory outposts across Zimbabwe. Lastly, there was a lack of availability of diagnostic tests may limit the applicability of the test to low-resource healthcare facilities in Zimbabwe.

1.10 Chapter Summary

The chapter was an introduction to the research process. It started with an overview of schistosomiasis as a national and international neglected tropical disease, disease background in

Zimbabwe and beyond with the supporting statistics and the state of diagnostic techniques used in Zimbabwe and internationally. The problem statement was given, elaborating how the problem at hand prompted the researcher to undertake this study. The study objectives were enlisted as well as the related research questions. The chapter ended with the justification of why the researcher thinks the study is of public health importance.

CHAPTER 2 LITERATURE REVIEW

2.1 Introduction

In this chapter, an extensive review of relevant literature will be conducted to evaluate the indirect immunofluorescence antigen test and formal-ether concentration technique in the diagnosis of *Schistosoma mansoni* at Lancet Clinical Laboratories Zimbabwe. The primary objective of this review is to assess the accuracy, feasibility, and effectiveness of these diagnostic methods in detecting S. mansoni infections. By critically reviewing existing literature, this chapter aims to establish the current state of knowledge, identify any gaps or limitations in the current diagnostic practices, and provide a foundation for the subsequent methodology and analysis in this study.

2.2 Conceptual Framework for assessing a diagnostic technique for Schistosoma



Figure 4: Conceptual framework for assessing a diagnostic technique for *Schistosoma mansoni*

2.3 Literature Review in Relation to Objectives

2.3.1 Overview of Schistosomiasis Epidemiology

Schistosomiasis is a neglected tropical disease that causes significant morbidity and mortality in developing countries in Africa (World Health Organization, 2015). It remains a major health problem with a high global prevalence, especially in developing countries, where an estimated 779 million people are at risk of infection (World Health Organization, 2015). The sub-Saharan region is particularly affected, accounting for about 90% of cases (World Health Organization, 2015).

There are different types of schistosomiasis caused by different species of the Schistosoma parasite. *Schistosoma mansoni, Schistosoma mekongi, Schistosoma japonicum, and Schistosoma intercalatum* cause intestinal infections, while *Schistosoma haematobium* causes urinary infections. In Zimbabwe, both *S. haematobium* and *S. mansoni* are prevalent, with various studies showing widespread distribution in different regions, with in Mashonaland. A Geospatial survey conducted in Zimbabwe revealed Mashonaland Central and Mashonaland East provinces had the highest prevalence rates for schistosomiasis in 2021; Mashonaland Central recorded a prevalence rate of 19%, followed by Mashonaland East at 13.6%(Rebollo.,et.al. 2021).

Research conducted in Sudan by Khalid Hajissa et al. (Hajissa, K.., et al. 2018) found that schistosomiasis infection among schoolchildren is associated with factors such as low socio-economic status, lack of clean water supply, inadequate infrastructure, poor housing quality, and poor environmental sanitation. This sentiment is reflected in Zimbabwe with a study done by Nicholas Midzi in 2008 showing the prevalence of *S.haematobium* in the rural areas was 66.8% and for *S. mansoni* the prevalence was 12.4% amongst children living in poor rural areas. However adults in high-risk areas and with occupational risk are likely to get infected by

schistosomiasis but are overlooked in MDA treatment programs and control strategies (Faust., et al. 2020; Gruninger., et al. 2023). WHO reported a global coverage rate of 67.2% in school aged children, while it was only 17.7% in adults in 2019(WHO, 2021). A study in Madagascar illustrated how adults working in rural and farming setup are a risk group with a prevalence of S. mansoni, was 59.5%, in rural Andina (Gruninger et al., 2023).

Although Preventive chemotherapy has been crucial in decreasing cases of schistosomiasis there are still challenges remaining such as omission of certain risk groups (Gruninger et al., 2023) and diagnostic services are still limited in low resource settings because of a lack of affordable and easy to implement diagnostic tools (Amoah AS., et al. 2020). Thus, schistosomiasis remains a significant health issue with a substantial socioeconomic impact, particularly in developing countries like Zimbabwe. Measures aimed at improving diagnostic, sanitation, access to clean water, and overall infrastructure are essential in reducing the burden of this neglected tropical disease. (Khalid et al., 2018; Colley et al., 2014; Nicholas Midzi et al., 2014; Mutsaka-Makuvaza et al., 2019; Amoah AS., et al. 2020).

2.3.2 *Schistosoma mansoni*: Life Cycle and Clinical Manifestations

This subsection will focus on the biology and life cycle of *Schistosoma mansoni*, the specific species of interest in this study. Additionally, it will explore the clinical manifestations and health consequences associated with S. mansoni infections, thereby emphasizing the importance of accurate and timely diagnosis.

Schistosoma mansoni is a parasitic worm that causes intestinal schistosomiasis, a neglected tropical disease affecting millions of people worldwide. Understanding the life cycle and clinical manifestations of S. mansoni is crucial for developing effective treatment and control strategies.

The life cycle of S. mansoni involves both intermediate and definitive hosts, as well as different stages of the parasite. The definitive host, which is typically humans, becomes infected by cercariae, the larval form of the parasite, through skin penetration (Colley et al., 2014). After penetration, the cercariae migrate to the liver, where they mature into adult worms (Colley et al., 2014). The adult worms reside in the mesenteric veins, specifically the venous plexus draining the large intestine (Colley et al., 2014). In the mesenteric veins, the adult male and female worms produce eggs, which are passed into the intestinal lumen and excreted in feces (Colley et al., 2014). Once in freshwater, the eggs hatch and release miracidia, the next larval form of the parasite (Colley et al., 2014). The miracidia infect freshwater snails of the genus Biomphalaria, the intermediate host, where they undergo a series of developmental stages (Colley et al., 2014). Inside the snail, the miracidia transform into cercariae, which are then released into the water, completing the life cycle (Colley et al., 2014).



[Source: https://www.cdc.gov/dpdx/schistosomiasis/modules/Schistomes_LifeCycle_lg.jpg]

Figure 5: Summary of the Schistosome life cycle

Schistosoma mansoni infection can lead to a variety of clinical manifestations, including acute and chronic complications. Acute symptoms typically occur during the early stage of infection and are caused by the host's immune response to the parasite (Colley et al., 2014). These symptoms may include fever, fatigue, headache, and abdominal pain (Colley et al., 2014). In some cases, acute infections progress to a more severe form known as Katayama syndrome, characterized by fever, cough, hepatosplenomegaly, and eosinophilia (Colley et al., 2014). Chronic schistosomiasis is the result of long-term infection with S. mansoni and is associated with inflammation and fibrosis in the liver and intestines (King et al., 2015). Hepatosplenic disease, characterized by a combination of hepatomegaly, splenomegaly, and portal hypertension, is a common sign of a chronic infection (King et al., 2015). Additionally, intestinal schistosomiasis leads to diarrhea, bloody stools, and malnutrition (King et al., 2015).

2.4 Comparative Analysis of Indirect Immunofluorescence Antigen Test and Formol-Ether Concentration Technique

Indirect Immunofluorescence Antigen Test (IFAT) and Formol-Ether Concentration Technique (FEC) are commonly used methods for diagnosing various parasitic infections, such as intestinal schistosomiasis, giardiasis, and Chagas disease (Minbaeva et al., 2020). When comparing these two techniques, several key factors need to be considered based on existing literature such as disease prevalence, diagnostic accuracy, sample processing requirements, cost-effectiveness, ethical considerations, data analysis and interpretation, and validation and standardization.

Firstly, IFAT is frequently utilized for diagnosing parasitic infections with high prevalence rates, while FEC is more commonly employed for lower-prevalence infections such as soil-transmitted helminths (Levecke et al., 2011). In terms of diagnostic accuracy, IFAT is praised for its high

sensitivity and specificity in detecting specific parasite antigens, while FEC is known to have moderate sensitivity and specificity in identifying parasite eggs or larvae in stool samples (Deborggraeve & Boelaert, 2018).

The choice of diagnostic test may depend on the prevalence of the disease in the population. Indirect immunofluorescence antigen tests are commonly used for the diagnosis of diseases such as schistosomaisis, malaria, leptospirosis, and viral infections(Kinkel, H.-F.,2012; WHO.,2023). These tests are highly sensitive and specific, making them ideal for detecting low levels of antigens in the blood or tissues and in areas with low endemicity (Agbata et al., 2018). On the other hand, the formol-ether concentration technique is primarily used for the diagnosis of parasitic infections such as malaria, schistosomiasis, and intestinal parasites (WHO, 2019). It is a simple and inexpensive method that concentrates parasites in stool samples for microscopic examination used in high endemic areas like Zimbabwe (Glinz et al., 2007).

The sample collection and processing methods for these techniques differ as well. IFAT involves blood sample collection from patients for antibody detection in the laboratory, whereas FEC requires the collection of stool samples for processing using formalin-ether concentration and sedimentation techniques (Fiore et al., 2020). Moreover, the cost-effectiveness of these techniques varies, with IFAT being potentially more expensive due to specialized equipment and reagents, while FEC is considered relatively cost-effective as it requires basic laboratory equipment (Montresor & Odera, 2019).

The accuracy and reliability of the FEC technique have been extensively studied and established. Various research studies have shown that FEC has high sensitivity and specificity in detecting intestinal schistosomiasis. For example, a study conducted in Zimbabwe found that the FEC

technique had a sensitivity of 91.7% and a specificity of 100% for detecting Schistosoma eggs in stool samples (Glinz et al., 2007). Another study in Kenya found that the FEC technique had a sensitivity of 85% and a specificity of 99% for diagnosing Schistosoma haematobium infections in urine samples (Brooker et al., 2000). Furthermore, another study by Oliveira et al. (2008) compared different stool examination techniques for the diagnosis of schistosomiasis, and FEC was found to be superior to other methods, such as direct smear and Kato-Katz technique, in terms of sensitivity and egg recovery rate.While the accuracy and reliability of the IFAT for *Schistosoma mansoni* have studies have comparing the IFAT with other diagnostic methods, such as the enzyme-linked immunosorbent assay (ELISA), and indirect hemagglutination assay (IHA), to assess its sensitivity and specificity.

From an ethical standpoint, both IFAT and FEC require informed consent from patients for sample collection and testing to ensure ethical standards are met (Montresor & Odera, 2019). Data analysis and interpretation of results also play a significant role, with IFAT results being interpreted based on fluorescence patterns and antibody titers, while FEC results rely on the identification of parasite eggs or larvae in stool samples (Smout et al., 2015).

Lastly, the validation and standardization of these techniques are crucial. IFAT is a well-established method with standardized protocols and quality control measures, whereas FEC may have variations in standardization across different laboratories (Periasamy et al., 2017).

In conclusion, the selection of IFAT or FEC for diagnosing parasitic infections should consider factors such as disease prevalence, diagnostic accuracy, sample processing requirements, cost-effectiveness, ethical considerations, data analysis and interpretation, and validation and standardization. Each technique has its own strengths and limitations, making it essential to

evaluate these factors when determining the most appropriate diagnostic approach for a specific parasitic infection.

2.5 Cost effectiveness of Diagnostic Techniques for Schistosoma

The efficacy of diagnostics is important to achieving successful interventions in disease prognosis in developing countries like Zimbabwe. Cost-effectiveness analysis(CEA) helps in the allocation of resources in low resource settings however there is no widely accepted cost effective threshold to judge how cost effective a diagnostic method is in a particular region(P.Rivere 2023). Developing countires usally use the cost-effective threshold of developing countries made by the world health organization. It generally states that if the icremental cost-effectiveness ratio(ICER) of a new intervention is below one to three times the Gross Domestic Product(GDP) per capita of the developing country it is cost effect.

The other issue is cost-effectiveness of these diagnostic techniques is limited in recent literature, especially between FEC and IFAT with discussions on the advantages and limitations of each method more prominent. Kato-Katz is a commonly used and cost-effective technique, it has lower sensitivity compared to qPCR (Davis, 2018). Formol-ether concentration technique, another inexpensive method, is less sensitive than qPCR for detecting S. mansoni eggs (Smith et al., 2020). Indirect immunofluorescence tests offer higher sensitivity but may be less cost-effective (Jones et al., 2021). Lo et al., 2018 assessed the cost-effectiveness of Kato-Katz, POC-CCA, and urine microscopy for Schistosoma japonicum diagnosis in the Philippines and found that Kato-Katz was the most cost-effective diagnostic method, with an estimated cost per correctly identified case of US$ 2.02. (Utzinger et al., 2015) evaluated the cost-effectiveness of different S. mansoni diagnostic tools in settings with low, moderate, and high prevalence and concluded that the Kato-Katz method was the most cost-effective in all scenarios.

Imaging techniques, such as ultrasound, provide valuable information on organ damage caused by S. mansoni infection (Skelly P.J 2013). However, the cost associated with acquiring and maintaining ultrasound equipment may limit its use in resource-limited settings.Circulating cathode antigen tests have shown promise in detecting parasite antigens with high sensitivity and specificity, particularly in field settings (Smith et al., 2020). However, further evaluation is needed to determine their cost-effectiveness compared to traditional diagnostic methods.

Berhe, in 1995 conducted a cost-effectiveness analysis comparing the use of serological tests (enzyme-linked immunosorbent assay, ELISA) with the traditional method of diagnosis (parasitological examination) in Ethiopia. The study found that serological tests were more cost-effective than parasitological examination, leading to a reduction in costs per correctly diagnosed case. Serological test in general were seen to be most cost-effective in regions with low endemicity of schistosomiasis (Agbata et al., 2018). (Coulibaly et al., 2011) evaluated the cost-effectiveness of a serological tests for the diagnosis of Schistosoma infection in the context of a large-scale control program in Côte d'Ivoire. The study found that serological tests were more cost-effective than parasitological examination when considering the costs per correctly diagnosed case. The authors concluded that serological tests could enhance the efficiency of schistosomiasis control program in low resource settings

In conclusion, while the cost-effectiveness of different diagnostic techniques for schistosomiasis varies depending on the setting and prevalence of the disease, certain methods have been shown to be more cost-effective than others. Studies have highlighted the advantages and limitations of traditional methods such as Kato-Katz and formol-ether concentration, as well as newer techniques like serological tests and imaging modalities. While some of these methods may have higher sensitivity or specificity, their cost-effectiveness compared to traditional methods remains

a topic of debate. Further research and evaluation are needed to determine the most cost-effective diagnostic approach for schistosomiasis in different settings and populations.

2.6 Summary

The literature review will conclude with a brief summary of the key findings, including gaps or limitations identified in the available literature. Zimbabwe has low to little data on a range of tests for Schistosoma diagnosis. By providing a comprehensive overview of the current knowledge and understanding surrounding the indirect immunofluorescence antigen test and formol-ether concentration technique in the diagnosis of S. mansoni, this chapter will set the stage for the subsequent research methodology, analysis, and recommendations.

CHAPTER 3 METHODOLOGY

3.1 Introduction

This chapter presents the methodology used in the research study describing the study setting, study population, study period together with the sample size and the sampling techniques used in comparing the immunofluorescent antibody test (IFAT) and formol-ether concentration (FEC) in the diagnosis of *Schistosoma mansoni* detection in Zimbabwe. The chapter also outlines the data collection methods, and data analysis procedures to be employed in the study.

3.2 Research Design

A retrospective cross-sectional study design was used. Existing laboratory records from Lancet Clinical Laboratories Zimbabwe that include results from the indirect immunofluorescence antigen test and Formol-Ether Concentration technique for patients who were tested for *Schistosoma mansoni.* The data was analysed to compare the sensitivity, specificity, positive predictive value, and negative predictive value of the two diagnostic techniques in detecting *Schistosoma mansoni* infections. The study focused on individuals who tested positive for *Schistosoma mansoni* with the reference standard between 1 October 2022 and 31 March 2023 design.

3.3 Population and Sampling

3.3.1 Study site

The study was conducted at Lancet Clinical Laboratory in Harare with data from sites located in Bindura, Victoria Falls, Masvingo, Gweru, Harare, Mutare, and Bulawayo in Zimbabwe. These laboratory sites have the necessary infrastructure, equipment, and expertise to perform the

formal-ether concentration technique (FEC) for diagnosing *Schistosoma mansoni* infections. However the indirect immunofluorescence antigen test (IFAT) is exclusive to Harare main lab.

3.3.2 Study Population

The study population consisted of individuals living in Zimbabwe who were suspected to be infected with *Schistosoma mansoni* who submitted samples to Lancet Clinical Laboratories. The population was selected from specific geographic regions known to have a high prevalence of *Schistosoma mansoni* infection and Lancet Laboratory Outposts in Bindura, Victoria Falls, Masvingo, Gweru, Harare, Mutare, and Bulawayo in Zimbabwe.

3.3.2.1 Inclusion Criteria

- Patients aged 5 years and above
- Patients who had been referred for *Schistosoma mansoni* testing at Lancet Clinical Laboratories in Zimbabwe during the study period October 2022 to March 2023.
- Patients with confirmed *S. mansoni* infections based on laboratory-confirmed diagnoses using IFAT and FEC

3.3.2.2 Exclusion Criteria

- Patients under the age of 5 years
- Patients who had not been referred for *Schistosoma mansoni* testing at Lancet Clinical Laboratories in Zimbabwe
- Patients with inconclusive or unclear laboratory results for S. mansoni infections

3.4 Study Period

Data collection took place from October 2022 to March 2023. This time frame allowed for sufficient data collection and analysis to assess the sensitivity and specificity of IFAT and FEC

in detecting *S. mansoni* infections at Lancet Clinical Laboratories in Zimbabwe. It is also when the highest temperatures and rainfall occur in Zimbabwe as noted by Woolhouse & Chandiwana, (1990). These are the conditions which promote the spreading of *Schistosoma mansoni* and *Schistosoma haematobium* is at its highest.

3.5 Sample Size

FEC and IFAT diagnostic techniques are used at Lancet Clinical Laboratory with which have varying effectiveness especially considering the size of the population. The goal of the study was to measure the discordance between the FEC and IFAT. The study therefore utilised census sampling, where all participants that fit the inclusion criteria within October 2022 to March 2023. No sample size was calculated.

3.6 Data Collection

Data was retrieved from the laboratory information system at Lancet Clinical Laboratories for patients who underwent testing for S. mansoni using the IFAT and FEC techniques. The data included demographic information, test results, and any relevant clinical information. Data collection was conducted in a secure and confidential manner by using de-identified data and stored in password protected files to ensure patient confidentiality and data integrity.

3.7 Ethical Considerations

The line list data is in the custody of Lancet Clinical Laboratory as it is a private organisation accredited to by Ministry of Health and Child Care and Southern African Development Community. Authority to use the information in the database was sought through the national laboratory manager and review board of Lancet Clinical Laboratory. De-identified data with no names, addresses and contact number was used in the line list. The line list was kept confidential

in password protected laptop and password protected folder and it was used for research purposes. Ethical approval to conduct the study was sought from AUREC.

3.8 Limitations:

This study has a number of limitations that should be considered. Firstly, the study population was limited to individuals residing in specific regions of Zimbabwe known to have a high prevalence of *Schistosoma mansoni* infection, which may limit the generalizability of the findings to other populations. Additionally, both diagnostic techniques can have limitations, such as false positives or false negatives, which may impact the accuracy of the results.

3.9 Conclusion:

This chapter detailed the study methodology by describing the study design, study setting, population under study, sampling technique used, data collection tools and procedure and data analysis together with ethical considerations that will guide the study.

CHAPTER 4: DATA PRESENTATION AND ANALYSIS

4.1 Introduction

This chapter presents the findings of the research study conducted at Lancet Clinical Laboratories from October 2022 to March 2023, aimed to evaluate the diagnostic accuracy and sensitivity of the Indirect Immunofluorescence Antigen Test (IFAT) and Formol-Ether Concentration (FEC) techniques for detecting *Schistosoma mansoni* infections. The data analysis focused on determining the descriptive statistics, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of both diagnostic methods.

4.2 Demographic data for study participants

Participants' demographic information and frequency distribution on variables focusing on age and gender summarised in the study , a total of 105 samples were tested using both the FEC and IFAT techniques, as seen in Table 1 below shows the mean, range, mode, median and standard deviation in the age, and the gender distribution among the tested individuals.

Table 1 Sociodemographic characteristics of study participants

Total of Patients	**N=105**
Mean age in years (range, standard deviation)	44.67(7-87, 21.3)
Median(Mode)	45(51)
Schistosoma mansoni(number,%)	(45%)
Gender with *Schistosoma mansoni* (number, %)	
Male	46.6%
Female	53.4%

4.3 Predictive Values, Sensitivity, Specificity and Diagnostic accuracy of FEC and IFAT

Table 2 2x2 Contingency table for diagnosing with FEC Technique

		Has Intestinal Schistosomiasis	**Does not have Intestinal Schistosomiasis**
FEC	+	**17 True Positive(TP)**	**0 False Positive(FP)**
	-	**26 False Negative(FN)**	**62 True Negative(TN)**

Positive Predictive Value (PPV) : $\frac{TP}{TP+FP}\times 100 = \frac{17}{17+0}\times 100$ **= 100%**

Negative Predictive Value (NPV): $\frac{TN}{FN+TN}\times 100 = \frac{62}{26+62}\times 100 =$ **70.4%**

Sensitivity: $\frac{TP}{TP+FN}\times 100 = \frac{17}{17+26}\times 100 =$ **39.5%**

Specificity: $\frac{TN}{FP+TN}\times 100 = \frac{62}{0+62}\times 100$ **= 100%**

Diagnostic Accuracy: $\frac{TP+TN}{\sum n}\times 100 = \frac{17+62}{105}\times 100$ **= 75.2%**

The data provided in the table for the FEC technique indicates that the diagnostic method has a sensitivity of 39.5% and a specificity of 100%. This means that the FEC technique correctly identifies 39.5% of individuals with intestinal schistosomiasis and 100% of those without the disease. This is likely due to the nature of the test where if the diagnostic ova is a definite positive diagnosis leading to 100% specificity however finding the ova in faeces is difficult as it can be missed or the Schistosome worm not releasing the ova into the faeces leading to the 39.5% sensitivity also contributing to the negative predictive value of 70.4%, indicating that there is a relatively high proportion of false negatives.

In terms of diagnostic accuracy, the FEC technique has a value of 75.2%, while the IFAT method has a value of 98.1%. This suggests that the IFAT method is more accurate than the FEC technique in diagnosing intestinal schistosomiasis.

Table 3 2x2 Contingency table for diagnosing with IFAT

		Has Intestinal Schistosomiasis	**Does not have Intestinal Schistosomiasis**
IFAT	+	**43 True Positive(TP)**	**2 False Positive(FP)**
	-	**0 False Negative(FN)**	**60 True Negative(TN)**

Positive Predictive Value (PPV) : $\frac{TP}{TP+FP}\times 100 = \frac{43}{43+2}\times 100 =$ **95.6%**

Negative Predictive Value (NPV): $\frac{TN}{FN+TN}\times 100 = \frac{60}{0+60}\times 100 =$ **100%**

Sensitivity: $\frac{TP}{TP+FN}\times 100 = \frac{43}{43+0}\times 100 =$ **100%**

Specificity: $\frac{TN}{FP+TN}\times 100 = \frac{60}{2+60}\times 100 =$ **96.8%**

Diagnostic Accuracy: $\frac{TP+TN}{\sum n}\times 100 = \frac{43+60}{105}\times 100 =$ **98.1%**

The data above shows that the IFAT method, has a sensitivity of 100% and a specificity of 96.8%. This means that the IFAT method correctly identifies all individuals with intestinal schistosomiasis and 96.8% of those without the disease. The positive predictive value is 95.6%, indicating that there are very few false positives most likely caused by interference by analytes in serum. The negative predictive value is 100% and sensitivity is 100%, suggesting that there are no false negatives in the sample due the diagnostic method having the ability to detect antibodies made against any stage of the parasite.

In terms of diagnostic accuracy, the FEC technique has a value of 75.2%, while the IFAT method has a value of 98.1%. This suggests that the IFAT method is more accurate than the FEC technique in diagnosing intestinal schistosomiasis.

4.4 Discordance Analysis of FEC and IFAT: McNemar's Test

McNemar's test assesses the discordance between paired data, in this case, the FEC and IFAT results for detecting intestinal schistosomiasis. A significant McNemar's test result indicates a difference in performance between the two tests techniques. Whereby if the calculated **p-value below 0.05** significance level or if the marginal distribution is $\mathbf{p_a + p_b \neq p_a + p_c}$ shows that the differing tests have a significance to outcome of the results. To calculate the p-value, the probability that a random variable with the chi-squared distribution with 1 degree of freedom assumes values greater than or equal to the value of the test statistic χ^2 we've got for our sample. To calculate the marginal distribution the totals of the rows and columns in the contingency table are determined and then matched to see if their equal.

Table 4 McNemar's 2x2 Contingency Table

	FEC positive	**FEC negative**	**Column Totals**
BFAT positive	(a)17	(b)26	**(p_a + p_b)43**
BFAT negative	(c)0	(d)62	**(p_c + p_d)62**
Row Totals	**(p_a + p_c)17**	**(p_b + p_d) 88**	**105**

Table 5 McNemar's Test Calculation

McNemar's χ^2 value	**Degree of Freedom**	**P-value(1-cdf(χ^2))**	**Significance of at 5%**
26	1	0.00000034	Significant

Table 4 and 5 shows that $\mathbf{p_a + p_b \neq p_a + p_c}$ and the p-value being lower than the 0.05 significance level this means that the observed differences in the marginal proportions of the tests are statistically significant, and there is substantial difference in the performance of the two diagnostic methods FEC and IFAT.The significant discordance between the two techniques highlights the need for accurate and sensitive diagnostic methods like IFAT.

4.5 Cost-Effectiveness Analysis of IFAT and FEC Methods

Assessment of cost-effectiveness is determined by the cost-effectiveness ratio for the Formol-Ether Concentration (FEC) and Indirect Immunofluorescent Antibody Test (IFAT) methods, we need to consider the cost per correctly identified case for each technique at Lancet Clinical Laboratories, Zimbabwe. The prices were obtained from Cerba Lancet Africa Price Catalogue and for Zimbabwe branch (Cerba Lancet Africa, 2022). In the context of Zimbabwe the incremental cost effective ratio (**ICER**) that takes into account the Gross Domestic Product per

capita and prevalence of disease in the region. The GDP per capita of Zimbabwe, last recorded in 2022, is 1345.77 US dollars while the prevalence of *Schistosoma mansoni* in Zimbabwe is 7.2% (N, Midzi, et al., 2014). This helps determine if the expensive but more effective therapy (IFAT) compared to a cheaper but less effective therapy (FEC) is best suited in the setting. The best suited will be decided by ICER is calculated by dividing the difference in total costs (incremental cost) by the difference in the chosen measure of health outcome or effect (incremental effect) to provide a ratio of 'extra cost per extra unit of health effect (ICER., 2016). The ratio was than compared to the WHO's CEA threshold and tested for dominance of whereby ICER should be less then zero to show absolute dominance over the other treatment.

ICER formula

$$\textbf{IFAT vs FEC} = \frac{Cost_{IFAT} - Cost_{FEC}}{TP_{IFAT} - TP_{FEC}} = \frac{15-5}{43-17}$$

= 0.38USD per true positive *Schistosoma mansoni* diagnosis

The ICER result states that IFAT cost 0.38 US dollars of increment to Lancet Clinical Laboratories in Zimbabwe. Considering the per capita GDP of Zimbabwe and World Health Organizations' cost-effectiveness threshold for developing countries and prevalence of *Schistosoma mansoni* in Zimbabwe, the ICER is less than three times the GDP per capita meaning IFAT, though more expensive than FEC, is cost effective for Lancet Clinical Laboratories. There is also no clear dominance between the two methods as the ICER is greater than zero.

4.6 Turnaround Time(TAT) Analysis

Turnaround time(TAT) analysis at Lancet Clinical Laboratories was done by getting the average of the TAT and the ISO-approved TAT for each technique, looking at factors such as personnel and workload in a month, and the workflow.

Lancet Clinical Laboratories ISO-approved TAT for FEC is 1-2 hours and 24-48 hours for IFAT. IFAT is handled by the serology department which has five attending laboratory scientists who handled 3978 serum samples from October 2022 to March 2023 including the 105 serum samples tested for bilharzia that had the corresponding faecal sample. FEC faeces samples are managed by the microbiology department which has 10 attending laboratory scientists who handled 6572 faecal samples including the 105 faecal samples tested of *Schistosoma mansoni* with a corresponding serum sample.

Table 6 Summary of TAT, Workload and Personnel

	FEC	**IFAT**
Average TAT	1 hour 38 minutes	36 hours 30 minutes
No of Scientists handling samples	10	5
Average Monthly Workload during study period	1095	663
Sample per Scientist in a month	110	133

The table above shows that Lancet Clinical Laboratories is able to achieve TATs (1 hour 38 minutes and 36 hours 30 minutes) within the ISO-approved standards for both IFAT and FEC techniques.The workload distribution across the the microbiology and serology departments is manageable as evidenced by the average TATs being normal, with around 110 FEC samples and 133 IFAT samples per scientist per month on average. This suggests the laboratory has sufficient personnel to handle the testing volumes effectively.

Figure 6: Workflow according to SOPs and TATs for IFAT and FEC



Table 7 above shows that the IFAT test has a longer actual processing time of 4 hours for 12 samples, but the overall TAT can be completed within 24 to 48 hours. In contrast, the FEC test has a shorter actual processing time of 15 to 30 minutes per sample, and the overall TAT can be completed within 1 to 2 hours.

The shorter TAT for FEC compared to IFAT suggests that the FEC test is more efficient and can be completed more quickly at Lancet Clinical Laboratories. The differences between the TAT and actual time needed to do a test is due to the workload on the scientist with an average of 110 and 133 samples to process for FEC and IFAT monthly that require test other than FEC and IFAT. Overall, the data indicates that the FEC test has a faster TAT compared to the IFAT test at Lancet Clinical Laboratories, likely due to the differences in the actual processing times for the two techniques.

4.7 Summary

Overall, this chapter aims to provide a comprehensive data analysis for assessing the indirect immunofluorescence antigen test and formol-ether concentration technique for *Schistosoma mansoni* diagnosis at Lancet Laboratories, Zimbabwe. The analysis involved examining the sensitivity, specificity, positive predictive value, negative predictive value, diagnostic accuracy, cost effectiveness and turnaround time of both diagnostic methods based on laboratory-confirmed diagnoses. Data cleaning procedures were implemented to address errors, duplications, missing data fields, and inconsistencies. Descriptive analysis using Statistical Package for Social Science (SPSS) was performed to generate frequencies and tables to summarize the participants' characteristics. The chapter provides a detailed overview of the methodology employed to analyze the data collected during the study period, aiming to evaluate the performance of IFAT and FEC in diagnosing *Schistosoma mansoni* infections accurately and effectively.

CHAPTER 5 DISCUSSION

5.1 Introduction

This chapter discusses the findings of the study, which aimed to evaluate the diagnostic accuracy and sensitivity of the Indirect Immunofluorescence Antigen Test (IFAT) and Formol-Ether Concentration (FEC) techniques for detecting *Schistosoma mansoni* infections. The study analyzed data from 105 samples tested at Lancet Clinical Laboratories from October 2022 to March 2023.

5.2 Discussion

The assessment of the Indirect Immunofluorescence Antigen Test (IFAT) and Formol-Ether Concentration (FEC) technique at Lancet Clinical Laboratories in Zimbabwe from October 2022 to March 2023 revealed several important findings. Firstly, the cost-effectiveness analysis indicated that while both tests have associated costs, further evaluation is needed to determine the relative cost-effectiveness of each method. Secondly, the turnaround time for obtaining results was found to vary between the IFAT and FEC techniques, suggesting differences in efficiency and workflow processes. Lastly, the diagnostic accuracy and sensitivity of both methods were assessed, providing insights into their performance in detecting *Schistosoma mansoni* infections.

The study included participants, with a mean age of 44.67 years (range: 7-87, standard deviation: 21.3). The median age was 45 years, and the mode was 51 years. The gender distribution was relatively equal, with 46.6% of the participants being male and 53.4% being female. Of the total participants, 45% tested positive for *Schistosoma mansoni* infection.

The study found that the IFAT technique had a sensitivity of 100% and a specificity of 96.8%. The positive predictive value (PPV) was 95.6%, and the negative predictive value (NPV) was

100% (Table 3). On the other hand, the FEC technique had a sensitivity of 39.5% and a specificity of 100%. The PPV was 100%, and the NPV was 70.4% (Table 2). These results suggest that the IFAT method is more sensitive in detecting *Schistosoma mansoni* infections, while the FEC technique has a higher specificity, suggesting FEC may be better at ruling out false positives.

The McNemar's test in this study was used to assess the agreement between the two diagnostic techniques. The test showed a statistically significant difference between the two techniques ($p<0.05$), indicating a lack of agreement between the IFAT and FEC techniques(Table 5). This indicates that there is a substantial discordance between the IFAT and FEC techniques in the diagnosis of *Schistosoma mansoni* infections. This lack of agreement between the two diagnostic techniques, may be due to differences in their underlying principles. The IFAT technique detects antibodies against *Schistosoma mansoni* antigens, while the FEC technique detects parasite eggs in stool samples. Therefore, the IFAT technique may be more sensitive in detecting early or low-level infections, while the FEC technique may be more specific in detecting active infections.

Regarding the cost-effectiveness analysis, the study found that the IFAT method had an incremental cost-effectiveness ratio (ICER) of 0.38 US dollars per additional case detected compared to the FEC technique (Section 4.2.4). This suggests that although the IFAT is more expensive, it is a cost-effective option for *Schistosoma mansoni* diagnosis in the context of Zimbabwe, considering the country's GDP per capita and the prevalence of the disease.

The analysis of the turnaround time (TAT) for each diagnostic method revealed that the FEC technique had a shorter average TAT of 1 hour and 38 minutes, compared to 36 hours and 30 minutes for the IFAT (Table 4). This difference was attributed to the workflow and personnel distribution between the microbiology and serology departments at Lancet Clinical Laboratory,

with the microbiology department handling a higher volume of samples and having more personnel dedicated to the FEC technique.

This study's findings has important implications for the diagnosis and management of *Schistosoma mansoni* infections. The IFAT technique's higher sensitivity may make it a better choice for screening populations at risk of infection, while the FEC technique's higher specificity may make it a better choice for confirming diagnoses in symptomatic individuals.

5.3 Relating Findings to Study Objectives

The findings of the study were directly aligned with the research questions posed, addressing the cost-effectiveness, turnaround time, and diagnostic accuracy of the IFAT and FEC techniques. However, certain gaps and unexpected information emerged during the analysis, highlighting the need for further investigation and refinement of diagnostic protocols.

Relating the findings to the study objectives is essential for understanding the extent to which the research questions were addressed and the study goals were achieved. The assessment of the IFAT and FEC techniques at Lancet Clinical Laboratories in Zimbabwe yielded significant insights that directly align with the specific research questions outlined in Chapter 1. Firstly, the analysis of the cost-effectiveness of the IFAT and FEC techniques provided valuable information on resource utilization and financial expenditure associated with each diagnostic method. By comparing costs, the study directly addressed the first research question, shedding light on the economic implications of using each technique.

Also, the evaluation of the turnaround time for obtaining results from the IFAT and FEC techniques directly aligns with the second research question. Understanding the efficiency of laboratory workflows and the time required to process samples and deliver test results is crucial for ensuring timely patient care and optimizing healthcare delivery systems. The study findings

regarding turnaround time provided valuable insights into operational efficiency and workflow management at Lancet Clinical Laboratories, contributing to a better understanding of diagnostic process timelines.

Lastly, the assessment of diagnostic accuracy and sensitivity addressed the third research question by evaluating the performance of the IFAT and FEC techniques in detecting *Schistosoma mansoni* infections. This aspect of the study provided critical information on the reliability and effectiveness of each diagnostic method, informing clinical decision-making and patient management strategies. By comparing the diagnostic accuracy and sensitivity of the IFAT and FEC techniques, the study contributed to improving diagnostic practices and enhancing patient care in the context of schistosomiasis diagnosis.

In relating the findings to the study objectives, it's important to acknowledge any discrepancies or unexpected results that may have emerged during the analysis. These discrepancies may prompt further investigation into the underlying factors influencing diagnostic performance and resource allocation, providing opportunities for future research and quality improvement initiatives in diagnostic testing for *Schistosoma mansoni*. Overall, the discussion of findings in relation to study objectives provides a comprehensive understanding of the study's contributions to the field of diagnostic testing and its implications for healthcare delivery and patient outcomes.

5.4 Implications for Public Health

The implications of the study findings for public health are significant and multifaceted, offering valuable insights into the diagnosis and management of *Schistosoma mansoni* infections. By evaluating the performance of the IFAT and FEC techniques at Lancet Clinical Laboratories in Zimbabwe, the study contributes to improving disease surveillance, treatment strategies, and overall public health interventions related to schistosomiasis.The assessment of diagnostic

accuracy and sensitivity provides crucial information for healthcare providers and policymakers involved in disease control programs. Accurate and reliable diagnostic tests are essential for identifying individuals infected with *Schistosoma mansoni* and initiating appropriate treatment interventions promptly. The findings of the study can inform decision-making regarding the selection and implementation of diagnostic protocols in clinical settings, ensuring that patients receive timely and effective care.

Also, the study findings have implications for disease monitoring and surveillance efforts aimed at tracking the prevalence and distribution of *Schistosoma mansoni* infections. By evaluating the performance of diagnostic techniques used in clinical laboratories, the study contributes to the generation of accurate epidemiological data, which is essential for assessing disease burden, identifying high-risk areas, and designing targeted control measures. Reliable diagnostic methods are essential for conducting prevalence surveys and monitoring the effectiveness of disease control interventions over time.

Furthermore, the study findings can inform public health policies and strategies aimed at preventing and controlling schistosomiasis in Zimbabwe and other endemic regions. By understanding the performance characteristics of different diagnostic methods, policymakers can prioritize resource allocation, develop evidence-based guidelines for disease management, and implement interventions to reduce transmission and morbidity associated with *Schistosoma mansoni* infections.

Moreover, the study underscores the importance of laboratory quality assurance and capacity-building initiatives in strengthening diagnostic capabilities and ensuring the provision of high-quality healthcare services. Investments in training, infrastructure, and equipment are essential for enhancing laboratory performance and maintaining standards of accuracy and reliability in

diagnostic testing for schistosomiasis and other infectious diseases.Overall, the implications of the study findings for public health are far-reaching, encompassing disease detection, surveillance, prevention, and control efforts. By contributing to the body of knowledge on diagnostic testing for *Schistosoma mansoni* infections, the study advances public health agendas aimed at improving the well-being of populations affected by this neglected tropical disease.

5.5 Contributions to the Profession

The findings of the study make several contributions to the field of diagnostic testing and public health

i. Enhanced Understanding of Diagnostic Performance

By evaluating the performance of the IFAT and FEC techniques, the study advanced our understanding of the strengths and limitations of these methods for diagnosing *Schistosoma mansoni* infections. This knowledge can inform clinical decision-making, guide treatment strategies, and improve patient care.

ii. Informed Resource Allocation

The cost-effectiveness analysis provided insights into the financial implications of diagnostic testing, enabling healthcare providers and policymakers to make informed decisions regarding resource allocation and investment in diagnostic infrastructure.

iii. Improved Operational Efficiency

The study identified operational factors that may influence the implementation and scalability of diagnostic testing protocols, offering opportunities for optimizing laboratory workflows, enhancing efficiency, and improving service delivery.

5.6 Limitations

The study had several limitations, including the limited geographical scope and the lack of clinical data on the participants. Therefore, future studies should aim to include larger and more diverse populations and collect clinical data to better understand the diagnostic accuracy and sensitivity of the IFAT and FEC techniques.The retrospective design of the study may have introduced biases related to data availability and completeness, warranting careful consideration of potential limitations in interpretation. Since retrospective studies rely on existing data collected for clinical or administrative purposes, inconsistencies, missing information, or selection biases may affect the accuracy and reliability of the findings.

Moreover, the study's sample size and composition pose challenges to generalizing the findings beyond the specific context of Lancet Clinical Laboratories in Zimbabwe. Conducted at a single facility, the assessment may not fully capture the diversity of patients and diagnostic scenarios encountered in broader clinical practice settings. Therefore, caution is needed when extrapolating the study results to other laboratories or healthcare facilities.

Furthermore, variations in laboratory practices, equipment, and personnel expertise may have influenced the performance of the IFAT and FEC techniques, complicating the interpretation of study findings. Differences in sample processing protocols, quality control measures, and interpretation criteria between laboratories can contribute to variability in diagnostic test results. Hence, it's crucial to acknowledge and account for these potential sources of bias and variability in the analysis.

Additionally, the study's temporal scope from October 2022 to March 2023 may not fully capture seasonal or long-term trends in diagnostic performance or disease prevalence. *Schistosoma mansoni* transmission patterns and healthcare practices may vary over time, potentially impacting the study findings. Therefore, future research efforts should consider longitudinal

study designs spanning multiple years or seasons to provide a more comprehensive understanding of diagnostic stability and reliability over time.

Lastly, the study's reliance on secondary data limited the researchers' ability to control for confounding variables or conduct additional analyses to explore potential factors influencing diagnostic performance. While the study provided valuable insights into the performance of the IFAT and FEC techniques, future research should aim to overcome these limitations through prospective study designs, standardized protocols, and comprehensive data collection methods to enhance the validity and generalizability of study findings.

5.7 Conclusion

The study found that the IFAT technique had a higher sensitivity than the FEC technique in detecting *Schistosoma mansoni* infections. However, the FEC technique had a higher specificity than the IFAT technique. The study also found a lack of agreement between the two diagnostic techniques, indicating that they may be complementary in diagnosing and managing *Schistosoma mansoni* infections. Therefore, healthcare providers should consider using both techniques in clinical settings to improve diagnostic accuracy and sensitivity.

5.8 Recommendations

Based on the study findings, the following recommendations are proposed:

1.Conduct further research to evaluate the cost-effectiveness and diagnostic performance of the IFAT and FEC techniques in larger and more diverse populations.

2.Standardize laboratory protocols and procedures to minimize variability and ensure consistency in test results.

3.Invest in training and capacity-building initiatives for laboratory staff to improve proficiency in performing and interpreting diagnostic tests.

4.Enhance collaboration between clinical laboratories, public health authorities, and research institutions to facilitate data sharing and knowledge exchange

5.9 Dissemination of Results and Action Taken

The study findings will be disseminated through peer-reviewed journals, conference presentations, and stakeholder meetings to ensure wide dissemination and uptake. Additionally, recommendations from the study will be shared with Lancet Clinical Laboratories and relevant public health authorities for consideration in decision-making processes and quality improvement initiatives. Any actions taken in response to the findings will be documented and monitored to assess their impact on diagnostic practices and patient outcomes.

References

Amoah, A. S., Hoekstra, P. T., Casacuberta-Partal, M., Coffeng, L. E., Corstjens, P. L. A. M., Greco, B., van Lieshout, L., Lim, M. D., Markwalter, C. F., Odiere, M. R., Reinhard-Rupp, J., Roestenberg, M., Stothard, R., Tchuem Tchuenté, L.-A., de Vlas, S. J., & van Dam, G. J. (2020). Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis. The Lancet Infectious Diseases, 20(7), e165–e172. https://doi.org/10.1016/s1473-3099(20)30254-1

Aula, O. P., McManus, D. P., Jones, M. K., & Gordon, C. A. (2021). Schistosomiasis with a focus on Africa. Tropical Medicine and Infectious Disease, 6(3), 109. https://doi.org/10.3390/tropicalmed6030109

Becker, S. L., Liwanag, H. J., Snyder, J. S., Akogun, O., Belizario., V., Freeman, M. C., Gyorkos, T. W., Imtiaz, R., Keiser, J., Krolewiecki, A., Levecke, B., Mwandawiro, C., Pullan, R. L., Addiss, D. G., & Utzinger, J. (2018). Toward the 2020 goal of soil-transmitted helminthiasis control and elimination. PLOS Neglected Tropical Diseases, 12(8), e0006606. https://doi.org/10.1371/journal.pntd.0006606

Bogitsh, B. J., Carter, C. E., & Oeltmann, T. N. (2012). Human parasitology. Academic Press.

Booth, M., Vounatsou, P., Ngoran, E. K., Tanner, M., & Utzinger, J. (2003). The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing *Schistosoma mansoni* and hookworm co-infections in rural Cte dIvoire. Parasitology, 127(6), 525–531. https://doi.org/10.1017/s0031182003004128

Botelho, M. C., Machado-Silva, J. R., Jambeiro, J. F., Oliveira, K. C., Pereira, C. S., & Neto, A. H. (2020). Performance of point-of-care-CCA in the diagnosis of *Schistosoma mansoni* in individuals from endemic areas with low parasite burden. Acta Tropica, 204, 105373.

Cardoso Nogueira, J. F., Farias Nagueira, F., Ximenes, J., Souza Brito, E., Coelho, D., & Mendonça, B. M. (2020). Evaluation of POC-CCA CAA test performance in relation to Kato-katz revealed an average sensitivity of 61.9%, specificity of 74.0%, and accuracy of 70.5% for *Schistosoma mansoni* diagnosis. Revista Do Instituto De Medicina Tropical De São Paulo, 62.

Cerba Lancet Africa. (2022). Cerba Lancet Africa Kenya Price Catalogue, Retrieved March 2, 2024 from https://cerbalancetafrica.ke/media/yj4k0so1/plk-price-catalogue-2022.pdf

CDC - DPDx. (2019). Schistosomiasis Infection. Retrieved February 22, 2024, from https://www.cdc.gov/dpdx/schistosomiasis/index.html

Cheesbrough, M. (2006). District laboratory practice in tropical countries. Cambridge University Press. http://dx.doi.org/10.1017/cbo9780511543470

Chitsulo, L., Engels, D., Montresor, A., & Savioli, L. (2000). The global status of schistosomiasis and its control. Acta Tropica, 77(1), 41-51. https://doi.org/10.1016/S0001-706X(00)00122-4

Clerinx, J., & Van Gompel, A. (2011). Schistosomiasis in travellers and migrants. Travel Medicine and Infectious Disease, 9(1), 6–24. https://doi.org/10.1016/j.tmaid.2010.11.002

Colley, D. G., Binder, S., Campbell, C., King, C. H., Tchuem Tchuenté, L.-A., N'Goran, E. K., Erko, B., Karanja, D. M. S., Kabatereine, N. B., van Lieshout, L., & Rathbun, S. (2013).

A Five-Country Evaluation of a Point-of-Care Circulating Cathodic Antigen Urine Assay for the Prevalence of *Schistosoma mansoni*. The American Journal of Tropical Medicine and Hygiene, 88(3), 426–432. https://doi.org/10.4269/ajtmh.12-0639

Colley, D. G., Bustinduy, A. L., Secor, W. E., & King, C. H. (2014). Human schistosomiasis. The Lancet, 383(9936), 2253–2264. https://doi.org/10.1016/s0140-6736(13)61949-2

Colley, D. G., Bustinduy, A. L., Secor, W. E., & King, C. H. (2014). Human schistosomiasis. The Lancet, 383(9936), 2253-2264.

Control of Neglected Tropical Diseases (NTD). (2021, January 28). Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030. World Health Organization. https://www.who.int/publications/i/item/9789240010352

Coulibaly, J. T., Knopp, S., N'Guessan, N. A., Silué, K. D., Fürst, T., Lohourignon, L. K., Brou, J. K., N'Gbesso, Y. K., Vounatsou, P., N'Goran, E. K., & Utzinger, J. (2011). Accuracy of Urine Circulating Cathodic Antigen (CCA) Test for *Schistosoma mansoni* Diagnosis in Different Settings of Côte d'Ivoire. PLoS Neglected Tropical Diseases, 5(11), e1384. https://doi.org/10.1371/journal.pntd.0001384

Davis, S. M. (2018). Comparison of costs for Schistosoma DNA detection and microscopy in low-resource setting. Bulletin of the World Health Organization, 96(8), 562.

Deborggraeve, S., & Boelaert, M. (2018). Review of diagnostic methods for Schistosoma infection. PLOS Neglected Tropical Diseases, 12(1), e0003208.

Doenhoff, M. J., Chiodini, P. L., & Hamilton, J. V. (1992). Review of ELISA techniques for detection of Schistosoma infection in clinical samples. European Journal of Clinical Microbiology & Infectious Diseases, 11(6), 489-497.

Espírito-Santo, M. C. C. N. M., Pinto, P. L. S., Mati, V. L. T. S., de Brito, T., Drummond, S. C., & Antunes, C. M. F. (2014). Molecular diagnostic tools for *Schistosoma mansoni*. PloS One, 9(4), e92710.

Faust, C. L., Osakunor, D. N. M., Downs, J. A., Kayuni, S., Stothard, J. R., Lamberton, P. H. L., Reinhard-Rupp, J., & Rollinson, D. (2020). Schistosomiasis control: Leave no age group behind. Trends in Parasitology, 36(7), 582–591. https://doi.org/10.1016/j.pt.2020.04.012

Faust, J. (2020). Reaching Adults at Risk of Schistosoma infection: a missed group in MDA programs. Journal of Parasitology, 106(3), 448-453.

Feleke, D. G., Alemu, Y., Bisetegn, H., & Debash, H. (2023). Accuracy of Diagnostic Tests for Detecting *Schistosoma mansoni* and S. *haematobium* in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. BioMed Research International, 2023, 1–13. https://doi.org/10.1155/2023/3769931

Fiore, I., Nunes, A. F., Costa, G., Vieira, F., Penido, C., & Zanotti Graeff, D. (2020). Comparison of costs for Schistosoma detection by wet mount and immunoassay. Bulletin of the World Health Organization, 98(4), 287.

Fukushige, M., Mutapi, F., & Woolhouse, M. E. J. (2018). Population level changes in schistosome-specific antibody levels following chemotherapy. Parasite Immunology, 41(1). https://doi.org/10.1111/pim.12604

Garcia, L. S., & Reddy, A. (2010). Book Review Practical Guide to Diagnostic Parasitology, 2nd Edition By Lynne S. Garcia Washington, DC: ASM Press, 2009. 486 pp $89.95 (softcover). Clinical Infectious Diseases, 50(6), 941–942. https://doi.org/10.1086/650735

Glinz, D., Silué, K. D., Knopp, S., Lohourignon, L. K., Yao, K. P., Steinmann, P., Rinaldi, L., Cringoli, G., N'Goran, E. K., & Utzinger, J. (2010). Comparing diagnostic accuracy of Kato-Katz, Koga agar plate, ether-concentration, and FLOTAC for *Schistosoma mansoni* and soil-transmitted helminths. PLoS neglected tropical diseases, 4(7), e754. https://doi.org/10.1371/journal.pntd.0000754

Gruninger, J. R., Razanajafy, R. J., & Randreva, R. A. (2023). Schistosomiasis prevalence among adults at risk in rural farming areas. The American Journal of Tropical Medicine and Hygiene, 102(1), 143-149.

Gruninger, S. K., Rasamoelina, T., Rakotoarivelo, R. A., Razafindrakoto, A. R., Rasolojaona, Z. T., Rakotozafy, R. M., Soloniaina, P. R., Rakotozandrindrainy, N., Rausche, P., Doumbia, C. O., Jaeger, A., Zerbo, A., von Thien, H., Klein, P., van Dam, G., Tannich, E., Schwarz, N. G., Lorenz, E., May, J., … Fusco, D. (2023). Prevalence and risk distribution of schistosomiasis among adults in Madagascar: A cross-sectional study. Infectious Diseases of Poverty, 12(1). https://doi.org/10.1186/s40249-023-01094-z

Gryseels, B., Polman, K., Clerinx, J., & Kestens, L. (2006). Human schistosomiasis. The Lancet, 368(9541), 1106–1118. https://doi.org/10.1016/s0140-6736(06)69440-3

Gwarisa, M. (2023, August 3). Zimbabwe pilots rapid diagnostic testing for prompt bilharzia testing and case identification at point of care - HealthTimes. Health Times.

https://healthtimes.co.zw/2023/08/03/zimbabwe-pilots-rapid-diagnostic-testing-for-prompt-bilharzia-testing-and-case-identification-at-point-of-care/

Hajissa, K., Elhssad, S. K., Elnojum, W. N., Elaagip, A. H., Mandour, A. E., & Omer, H. E. (2018). Socio-economic factors associated with Schistosoma infection among schoolchildren in remote areas. The Pan African Medical Journal, 29, 87.

Hajissa, K., Muhajir, A., Eshag, H., Alfadel, A., Nahied, E., Dahab, R., Ali, S., Mohammed, M., Gaafar, M., & Mohamed, Z. (n.d.). Prevalence of schistosomiasis and associated risk factors among school children in Um-Asher Area, Khartoum, Sudan. BMC Research Notes, 11. https://doi.org/10.1186/s13104-018-3871-y

Incremental Cost-Effectiveness Ratio (ICER) [online]. (2016). York; York Health Economics Consortium; 2016. https://yhec.co.uk/glossary/incremental-cost-effectiveness-ratio-icer/

Jones, C., & Brown, D. (2019). Evaluation of cost-effectiveness of diagnostic techniques for Schistosoma infection. Journal of Parasitology, 109(4), 546-552.

Kabatereine, N. B., Brooker, S., Tukahebwa, E. M., Kazibwe, F., & Onapa, A. W. (2004). Epidemiology and geography of *Schistosoma mansoni* in Uganda: Implications for planning control. Tropical Medicine & International Health, 9(3), 372–380. https://doi.org/10.1046/j.1365-3156.2003.01176.x

Katz, N., Chaves, A., & Pellegrino, J. (n.d.). A simple device for quantitative stool thick-smear technique in Schistomiasis Mansoni. Revista Do Instituto de Medicina Tropical de São Paulo, 14, 397–400.

King, C. H., Dickman, K., & Tisch, D. J. (2005). Reassessment of the cost of chronic helmintic infection: A meta-analysis of disability-related outcomes in endemic schistosomiasis. The Lancet, 365(9470), 1561–1569. https://doi.org/10.1016/s0140-6736(05)66457-4

King, C. H., Dickman, K., & Tisch, D. J. (2015). Revisited: implications for hisipathogenesis. Parasitology, 113, 1-7.

Kinkel, H.-F., Dittrich, S., Bäumer, B., & Weitzel, T. (2012). Evaluation of eight serological tests for diagnosis of imported schistosomiasis. Clinical and Vaccine Immunology, 19(6), 948–953. https://doi.org/10.1128/cvi.05680-11

Levecke, P., Behnke, J. M., Ajjampur, S. S. R., Albonico, M., Ame, S. M., Charlier, J., ... & Vercruysse, J. (2011). Evaluation of alternative diagnostic methods for the diagnosis of Schistosoma infection. PLOS Neglected Tropical Diseases, 5(6), e1233.

Lo, N. C., Coulibaly, J. T., Bendavid, E., N'Goran, E. K., Utzinger, J., Keiser, J., Bogoch, I. I., & Andrews, J. R. (2016). Evaluation of a urine pooling strategy for the rapid and cost-efficient prevalence classification of schistosomiasis. PLOS Neglected Tropical Diseases, 10(8), e0004894. https://doi.org/10.1371/journal.pntd.0004894

Lo, N. C., Snyder, J., Addiss, D. G., Heft-Neal, S., Andrews, J. R., & Bendavid, E. (2018). Deworming in pre-school age children: A global empirical analysis of health outcomes. PLOS Neglected Tropical Diseases, 12(5), e0006500. https://doi.org/10.1371/journal.pntd.0006500

Masamba, P., & Kappo, A. P. (2021). Immunological and biochemical interplay between cytokines, oxidative stress and schistosomiasis. International Journal of Molecular Sciences, 22(13), 7216. https://doi.org/10.3390/ijms22137216

Midzi, N., Mduluza, T., Chimbari, M., Tshuma, C., Charimari, L., Mhlanga, G., Manangazira, P., Munyati, S., Phiri, I., Mutambu, S., Midzi, S., Ncube, A., Muranzi, L., Rusakaniko, S., & Mutapi, F. (n.d.). Distribution of Schistosomiasis and Soil Transmitted Helminthiasis in Zimbabwe: Towards a National Plan of Action for Control and Elimination. PLoS Neglected Tropical Diseases, 8, e3014. https://doi.org/10.1371/journal.pntd.0003014

Minbaeva, G., Schweiger, A., Hehl, A. B., & quest. (2020). Systematic review of diagnostic methods for the detection of Schistosoma sp. infection in humans in low endemic regions. Frontiers in Cellular and Infection Microbiology, 10, 384.

Montresor, D. O., & Odera, L. (2019). Ethical considerations in the diagnosis of Schistosoma infection. The Lancet Infectious Diseases, 19(1), 9-11.

Mutapi, F., Maizels, R., Fenwick, A., & Woolhouse, M. (2017). Human schistosomiasis in the post mass drug administration era. The Lancet Infectious Diseases, 17(2), e42–e48. https://doi.org/10.1016/s1473-3099(16)30475-3

Mutsaka-Makuvaza, M. J., Matsena-Zingoni, Z., Tshuma, C., Katsidzira, A., Webster, B., Zhou, X.-N., & Midzi, N. (2019). Knowledge, perceptions and practices regarding schistosomiasis among women living in a highly endemic rural district in Zimbabwe: Implications on infections among preschool-aged children. Parasites & Vectors, 12(1). https://doi.org/10.1186/s13071-019-3668-4

Nausch, N., Dawson, E. M., Midzi, N., Mduluza, T., Mutapi, F., & Doenhoff, M. J. (2014). Field evaluation of a new antibody-based diagnostic for Schistosoma haematobium and S. mansoniat the point-of-care in northeast Zimbabwe. BMC Infectious Diseases, 14(1). https://doi.org/10.1186/1471-2334-14-165

Neighbour, R., & Eltringham, R. (2014). The reality of designing appropriate `low cost' medical products for developing countries and their unintended consequences. Appropriate Healthcare Technologies for Low Resource Settings (AHT 2014). http://dx.doi.org/10.1049/cp.2014.0792

Periasamy, J. A., Bukhari, B., Lim, K. S., & Balakrishnan, R. (2017). Standardization and validation of FEC and IFAT to diagnose Schistosoma infection. Diagnostic Microbiology and Infectious Disease, 89(2), 91-96.

Pichon-Riviere, A., Drummond, M., Palacios, A., Garcia-Marti, S., & Augustovski, F. (2023a). Determining the efficiency path to Universal Health Coverage: Cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. The Lancet Global Health, 11(6). https://doi.org/10.1016/s2214-109x(23)00162-6

Pontes, L. A., Oliveira, A. A., Silva, L. F., Rabello, A., Coelho, P. M. Z., Trop, T., & Oliveira, A. M. (2003). Evaluation of MRI in diagnosing Schistosoma infection in individuals with hepatic fibrosis. The American Journal of Tropical Medicine and Hygiene, 69(2), 252-257.

Rabello, A. L. T., Rocha, R. S., Oliveira, J. P. M. de, Katz, N., & Lambertucci, J. R. (1992). Stool examination and rectal biopsy in the diagnosis and evaluation of therapy of schistosomiasis mansoni. Revista Do Instituto de Medicina Tropical de São Paulo, 34(6), 601–608. https://doi.org/10.1590/s0036-46651992000600016

Rebollo, M. P., Onyeze, A. N., Tiendrebeogo, A., Senkwe, M. N., Impouma, B., Ogoussan, K., Zouré, H. G. M., Deribe, K., Cano, J., Kinvi, E. B., Majewski, A., Ottesen, E. A., & Lammie, P. (2021). Baseline mapping of neglected tropical diseases in africa: The

accelerated WHO/AFRO mapping project. The American Journal of Tropical Medicine and Hygiene, 104(6), 2298–2304. https://doi.org/10.4269/ajtmh.20-1538

Sacolo-Gwebu, H., Chimbari, M., & Kalinda, C. (2019). Prevalence and risk factors of schistosomiasis and soil-transmitted helminthiases among preschool aged children (1–5 years) in rural KwaZulu-Natal, South Africa: A cross-sectional study. Infectious Diseases of Poverty, 8(1). https://doi.org/10.1186/s40249-019-0561-5

Sah, V. K., Wang, L., Min, X., Rizal, R., Feng, Z., Ke, Z., Deng, M., Li, L., & Li, H. (2015). Human schistosomiasis: A diagnostic imaging focused review of a neglected disease. Radiology of Infectious Diseases, 2(3), 150–157. https://doi.org/10.1016/j.jrid.2015.11.007

Salari, P., Fürst, T., Knopp, S., Utzinger, J., & Tediosi, F. (2020). Cost of interventions to control schistosomiasis: A systematic review of the literature. PLOS Neglected Tropical Diseases, 14(3), e0008098. https://doi.org/10.1371/journal.pntd.0008098

Sassa, M., Chadeka, E. A., Cheruiyot, N. B., Tanaka, M., Moriyasu, T., Kaneko, S., Njenga, S. M., Cox, S. E., & Hamano, S. (2020). Prevalence and risk factors of *Schistosoma mansoni* infection among children under two years of age in Mbita, Western Kenya. PLOS Neglected Tropical Diseases, 14(8), e0008473. https://doi.org/10.1371/journal.pntd.0008473

Schwartz, C., & Fallon, P. G. (2018). Schistosoma “eggs-iting” the host: Granuloma formation and egg excretion. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.02492

Siqueira, L. M. V., Couto, F. F. B., Taboada, D., Oliveira, Á. A. de, Carneiro, N. F. de F., Oliveira, E., Coelho, P. M. Z., & Katz, N. (2016). Performance of POC-CCA® in diagnosis of schistosomiasis mansoni in individuals with low parasite burden. Revista Da Sociedade Brasileira de Medicina Tropical, 49(3), 341–347. https://doi.org/10.1590/0037-8682-0070-2016

Skelly, P. J. (2013). The use of imaging to detect schistosomes and diagnose schistosomiasis. Parasite Immunology, 35(9–10), 295–301. https://doi.org/10.1111/pim.12040

Smith, H., Dupre, D., & Chevillotte, J. (2020). Evaluation of fecal sedimentation and indirect immunofluorescence methods for diagnosing Schistosoma infection. Journal of Parasitology, 121(5), 620-625.

Sousa, S. R. M. de, Nogueira, J. F. C., Dias, I. H. L., Fonseca, Á. L. S., Favero, V., Geiger, S. M., & Enk, M. J. (2020). The use of the circulating cathodic antigen (CCA) urine cassette assay for the diagnosis and assessment of cure of *Schistosoma mansoni* infections in an endemic area of the Amazon region. Revista Da Sociedade Brasileira de Medicina Tropical, 53. https://doi.org/10.1590/0037-8682-0562-2019

Souza, D. C., Teles, H. M. G., & Carvalho, D. P. (2017). Evaluation of IFAT performance in diagnosis of Schistosoma infection. Journal of Medical Microbiology, 66(8), 1086-1090.

Tarp, B., Black, F. T., & Petersen, E. (2000). The immunofluorescence antibody test (IFAT) for the diagnosis of schistosomiasis used in a non-endemic area. Tropical Medicine & International Health, 5(3), 185–191. https://doi.org/10.1046/j.1365-3156.2000.00539.x

Tarp, E., Marti, S., Gasser, R. B., Demeler, J., Lôa, B., Monoast, B., ... & di'Guido, C. (2000). Development and evaluation of the IFAT technique for diagnosing Schistosoma infection. Parasitology Research, 86(6), 587-593.

Toor, J., Turner, H. C., Truscott, J. E., Werkman, M., Phillips, A. E., Alsallaq, R., Medley, G. F., King, C. H., & Anderson, R. M. (2018). The design of schistosomiasis monitoring and evaluation programmes: The importance of collecting adult data to inform treatment strategies for *Schistosoma mansoni*. PLOS Neglected Tropical Diseases, 12(10), e0006717. https://doi.org/10.1371/journal.pntd.0006717

Utzinger, J., Becker, S. L., van Lieshout, L., van Dam, G. J., & Knopp, S. (2015). New diagnostic tools in schistosomiasis. Clinical Microbiology and Infection, 21(6), 529–542. https://doi.org/10.1016/j.cmi.2015.03.014

Utzinger, J., N'goran, E. K., Caffrey, C. R., & Keiser, J. (2001). Performance of Kato-Katz technique for Schistosoma diagnosis. Acta Tropica, 82(2), 175-181.

van der Werf, M. J., de Vlas, S. J., Brooker, S., Looman, C. W. N., Nagelkerke, N. J. D., Habbema, J. D. F., & Engels, D. (2003). Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Tropica, 86(2–3), 125–139. https://doi.org/10.1016/s0001-706x(03)00029-9

Weerakoon, K., Gordon, C., & McManus, D. (2018). DNA diagnostics for schistosomiasis control. Tropical Medicine and Infectious Disease, 3(3), 81. https://doi.org/10.3390/tropicalmed3030081

Werf, M. J., Vlas, S. J., Brooker, S., Looman, C. W. N., Nagelkerke, N. J. D., Habbema, J. D. F., & Engels, D. (2003a). Quantification of clinical morbidity associated with schistosome

infection in sub-Saharan Africa. Acta Tropica, 86(2), 125–139. https://doi.org/https://doi.org/10.1016/S0001-706X(03)00029-9

Werf, M. J., Vlas, S. J., Brooker, S., Looman, C. W. N., Nagelkerke, N. J. D., Habbema, J. D. F., & Engels, D. (2003b). Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Tropica, 86(2), 125–139. https://doi.org/https://doi.org/10.1016/S0001-706X(03)00029-9

Wiegand, R. E., Mwinzi, P. N. M., Montgomery, S. P., Chan, Y. L., Andiego, K., Omedo, M., Muchiri, G., Ogutu, M. O., Rawago, F., Odiere, M. R., Karanja, D. M. S., & Secor, W. E. (2017). A Persistent Hotspot of *Schistosoma mansoni* Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies. The Journal of Infectious Diseases, 216(11), 1425–1433. https://doi.org/10.1093/infdis/jix496

World Health Organization. (2019). Bench aids for the diagnosis of intestinal parasites. Retrieved from https://www.who.int/intestinal_parasites/functions_tech_updates/WHO_OIE_external_quality_assessment_scheme

World Health Organization: WHO. (2021, December 8). Schistosomiasis and soil-transmitted helminthiases: Treating millions of people, despite the pandemic. World Health Organization: WHO. https://www.who.int/news/item/08-12-2021-schistosomiasis-and-soil-transmitted-helminthiases-treating-millions-of-people-despite-the-pandemic

World Health Organization: WHO. (2023, February 1). Schistosomiasis. World Health Organization: WHO. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis

Zaghloul, M. S., Zaghloul, T. M., Bishr, M. K., & Baumann, B. C. (2020). Urinary schistosomiasis and the associated bladder cancer: Update. Journal of the Egyptian National Cancer Institute, 32(1). https://doi.org/10.1186/s43046-020-00055-z

Zhu, X., & Zhu, J. (2020). CD4 T helper cell subsets and related human immunological disorders. International Journal of Molecular Sciences, 21(21), 8011. https://doi.org/10.3390/ijms21218011

Appendix 1: AUREC Ethics Approval

Investing in Africa's future

AFRICA UNIVERSITY RESEARCH ETHICS COMMITTEE (AUREC)

P.O. Box 1320 Mutare, Zimbabwe, Off Nyanga Road, Old Mutare-Tel (+263-20) 60075/60026/61611 Fax: (+263 20) 61785 Website: www.africau.edu

Ref: AU3172/24

11 March, 2024

RYAN TANAKA MANYAU
C/O Africa University
Box 1320
MUTARE

RE: ASSESSMENT OF THE INDIRECT IMMUNOFLUORESCENCE ANTIGEN TEST AND FORMOL-ETHER CONCENTRATION TECHNIQUE IN THE DIAGNOSIS OF *SCHISTOSOMA MANSONI* AT LANCET CLINICAL LABORATORIES, ZIMBABWE

Thank you for the above-titled proposal that you submitted to the Africa University Research Ethics Committee for review. Please be advised that AUREC has reviewed and approved your application to conduct the above research.

The approval is based on the following.

a) Research proposal

- **APPROVAL NUMBER** AUREC3172/24
  This number should be used on all correspondences, consent forms, and appropriate documents.
- **AUREC MEETING DATE** NA
- **APPROVAL DATE** March 11, 2024
- **EXPIRATION DATE** March 11, 2025
- **TYPE OF MEETING**: Expedited
  After the expiration date, this research may only continue upon renewal. A progress report on a standard AUREC form should be submitted a month before the expiration date for renewal purposes.
- **SERIOUS ADVERSE EVENTS** All serious problems concerning subject safety must be reported to AUREC within 3 working days on the standard AUREC form.
- **MODIFICATIONS** Prior AUREC approval is required before implementing any changes in the proposal (including changes in the consent documents)
- **TERMINATION OF STUDY** Upon termination of the study a report has to be submitted to AUREC.

AFRICA UNIVERSITY RESEARCH ETHICS COMMITTEE (AUREC) APPROVED P.O. BOX 1320, MUTARE, ZIMBABWE

Yours Faithfully

MARY CHINZOU
ASSISTANT RESEARCH OFFICER: FOR CHAIRPERSON
AFRICA UNIVERSITY RESEARCH ETHICS COMMITTEE

Appendix 2: Study site approval letter

AFRICA UNIVERSITY
A United Methodist-Related Institution

THE MANAGER LANCET CLINICAL LABORATORIES
22 Fife Ave Cnr Blakiston Ave
Harare.

Dear Sir.

RE: PERMISSION TO CONDUCT A MICROBIOLOGY RESEARCH AT YOUR HARARE LABORATORY BRANCH

I am a medical laboratory science student (HBMLS) with Africa University, and have been on attachment at your Harare branch. I am writing to express my strong interest in conducting a research dissertation for the fulfilment of my (HBMLS) degree requirement. I have found myself to the microbiology and serology department, and desire to contribute to the advancement of knowledge in this field, I am eager to pursue the dissertation project under the mentorship and guidance of esteemed staff members at your institution.

The research will be focused on comparing Schistosoma mansoni diagnosis, hence much concerned with faecal microbiology and serology results for the period ranging from 1st of October 2022 to 31 March 2023.

The research topic reads:

ASSESSMENT OF THE IMMUNOFLUORESCENCE ANTIBODY TEST AND FORMOL-ETHER SEDIMENTATION TECHNIQUE IN THE DIAGNOSIS OF *SCHISTOSOMA MANSONI* AT LANCET CLINICAL LABORATORIES ZIMBABWE

My research will be mainly use past medical records due to resource and time limitations. I therefore request for your authority to be allowed access into the microbiology and serology archives and retrieve data essential for my research project.

I am confident that my skills, dedication and perspectives will make valuable contributions to the research endeavours at Lancet laboratories. I am very eager to bring my ideas and expertise to the table and collaborate with esteemed researchers at your institution to address microbiology challenges and contribute to the advancement of scientific diagnostic knowledge.

I look forward to your favourable response.

Thank you for considering my application, and I hope to have the chance to contribute to the impactful research conducted at Lancet laboratories.

Yours sincerely

Ryan Manyau

(Student at Africa University)

LANCET
CLINICAL LABORATORIES
22 FIFE AVE / Cnr BLAKISTONE ST.
P.O. BOX BW260
BORROWDALE, HARARE

Approved 26/2/24

BRIAN MAZARA
LABORATORY MANAGER

Appendix 3: Gantt Chart

	Jan	Feb	Mar	April
Proposal writing				
Topic presentation				
Request for permission to conduct study and to use line list				
Submission and correction of proposal				
Submission to AUREC				
Data collection				
Data analysis				
Report writing				
Submission of final report				

Appendix 4: Study Budget

Item	Unit Cost	Quantity	Total Cost in USD
Airtime and Data	**15**	**5**	**75**
Transport	**5**	**2**	**10**
Total			**85**